parecoxib has been researched along with Hypertension in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Elliott, WJ | 1 |
| Bulut, D; Hanefeld, C; Koll, R; Liaghat, S; Miebach, T; Mügge, A | 1 |
1 review(s) available for parecoxib and Hypertension
| Article | Year |
|---|---|
Do the blood pressure effects of nonsteroidal antiinflammatory drugs influence cardiovascular morbidity and mortality?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Humans; Hypertension; Isoxazoles; Lactones; Pyrazoles; Pyridines; Risk; Risk Factors; Sulfonamides; Sulfones | 2010 |
1 trial(s) available for parecoxib and Hypertension
| Article | Year |
|---|---|
Selective cyclo-oxygenase-2 inhibition with parecoxib acutely impairs endothelium-dependent vasodilatation in patients with essential hypertension.
Topics: Acetylcholine; Adult; Aged; Aspirin; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Endothelium, Vascular; Female; Forearm; Humans; Hypertension; Isoenzymes; Isoxazoles; Lysine; Male; Membrane Proteins; Middle Aged; Prostaglandin-Endoperoxide Synthases; Regional Blood Flow; Vasodilation; Vasodilator Agents | 2003 |